Leading ovarian cancer expert Dr Andrew Stephens appointed to Invion’s advisory board

 

  • Dr Andrew Stephens from Hudson Institute of Medical Research has accepted an appointment on Invion’s advisory board
  • Dr Stephens is one of Australia’s leading researchers in the area of ovarian cancer and heads the Ovarian Cancer Biomarkers Research Laboratory at Hudson Institute
  • His appointment provides Invion with a substantial resource in developing its licenced cancer treatment technology, PhotosoftTM
  • The appointment further strengthens the collaboration partnership between Invion and Hudson Institute
  • Invion is in the process of appointing other prominent cancer experts to the company

 

Brisbane, Australia and Delaware, United States, 21 March 2018: Invion Limited (ASX: IVX, “Invion” or “Company”) has appointed Dr Andrew Stephens, Group Head of the Ovarian Cancer Biomarkers Research Group at Hudson Institute of Medical Research, to its advisory board.

Dr Stephens is regarded as one of Australia’s foremost experts in the field of ovarian cancer research. He is Research Fellow at the Ovarian Cancer Research Foundation (OCRF) and a  Senior Research Affiliate (Honorary) with Epworth Healthcare.

His appointment is a significant milestone for Invion as it provides the Company with additional resources to develop its licensed cancer treatment technology, PhotosoftTM, and further strengthens the partnership between Invion and Hudson Institute of Medical Research.

Invion has signed a Research & Development Alliance Agreement with Hudson Institute, for collaboration on a range of projects on the PhotosoftTM technology, a next-generation Photo Dynamic Therapy (PDT), for the treatment of solid cancers.

Dr Stephens established the ovarian cancer biomarker group at Hudson Institute in 2009 after completing his PhD in the Department of Biochemistry at Monash University and undertaking a postdoctoral position at the University of Sydney using proteomics to discover novel antibiotic targets in bacteria.

“I am passionate about increasing the survival rates of ovarian cancer and finding better ways to treat and manage the disease,” said Dr Stephens.

“Early data from PhotosoftTM is encouraging and I look forward to working with Invion and building a strong scientific and medical basis for its future development. With carefully developed studies and positive results, this technology could lead to a novel way of targeting a number of cancers, including ovarian cancer.”

Dr Greg Collier, Managing Director and Chief Executive Officer of Invion, said: “We are very pleased to have an expert of Dr Stephens’ calibre on our advisory board and excited about the collaboration with Hudson Institute for the global development of PhotosoftTM.

“We are excited about the development PhotosoftTM , and focused on enhancing the Company’s scientific and medical expertise in the field of cancer to drive forward the asset’s research and clinical programs. We are looking to appoint several experts in the field of cancer research to key positions over the coming months.”

 

____________________________________________

 

Investor enquiries

Managing Director & CEO, Dr Greg Collier

T: +61 3 9081 6005

E: investor@inviongroup.com

 

Media enquiries

Brendon Lau

T: 0409 341 613

E: brendon@vantagepointpartners.com.au

 

About Invion

Invion is a clinical-stage life-sciences company that holds the license to the next-generation Photo Dynamic Therapy (PDT), PhotosoftTM, for the treatment of solid cancers. Research and clinical trials are funded by the technology licensor, The Cho Group, which will provide non-dilutive funding to the Company. Invion is listed on ASX (ASX:IVX).

About Hudson Institute of Medical Research

Hudson Institute of Medical Research is a top Australian biomedical research institute, recognised internationally for delivering better health through research into cancer, inflammation and reproduction and development. The Institute is home to 470 world-class scientists and students who push the boundaries of scientific knowledge to answer complex questions about human disease. Hudson Institute is a foundation member of the Monash Health Translation Precinct (MHTP), a major medical and scientific research hub based at the Monash Medical Centre in Melbourne’s south-eastern corridor. With its precinct partners, Monash Health and Monash University, Hudson Institute brings together world-leading scientists, clinicians and educators in a culture of collaboration and innovation that delivers research advances to benefit human health. The Precinct’s unique, end-to-end translational environment is supported by state-of-the-art laboratories, world leading technology platforms and a clinical trials centre in its $87.5 million MHTP Translational Research Facility.

 

Leading ovarian cancer expert Dr Andrew Stephens appointed to Invion’s advisory board

Posted in ASX Releases